https://doi.org/10.46344/JBINO.2026.v15i01.14

EMERGING BIOMARKERS AND MOLECULAR THERAPIES: THE NEXT FRONTIER IN SICKLE CELL ANEMIA CARE

***Emmanuel Ifeanyi Obeagu**

Department of Biomedical and Laboratory Science, Africa University, Mutare, Zimbabwe, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Biomedical and Laboratory Science, Africa University, Mutare, Zimbabwe, E-mail: emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161, +2348037369912

ABSTRACT

Sickle cell anemia represents a cornerstone in molecular medicine, where a single gene mutation gives rise to complex pathophysiological cascades encompassing hemolysis, vaso-occlusion, and organ dysfunction. Although conventional therapies such as hydroxyurea and blood transfusions have improved survival, they remain largely palliative. The advent of molecular diagnostics and therapeutic innovation has transformed the landscape of SCA care, ushering in an era of precision medicine. This narrative review explores the expanding repertoire of emergingbiomarkers—including inflammatory mediators, oxidative stress markers, and genetic modifiers—that provide insights into disease heterogeneity and therapeutic responsiveness. Concurrently, moleculartherapies, ranging from gene addition and CRISPR-based gene editing to RNA-targeted interventions and pharmacologic fetal hemoglobin inducers, are redefining curative potential. These advancements signal a shift from symptomatic management toward molecular correction and individualized treatment. Integrating biomarker discovery with gene-directed therapies holds the promise of achieving long-term remission and functional cure, positioning SCA at the forefront of translational hematology.

Keywords: Sickle Cell Anemia, Biomarkers, Molecular Therapy, Gene Editing, Precision Medicine

Introduction

Sickle cell anemia (SCA) is a monogenic yet multifactorial hematologic disorder that exemplifies the profound impact of a single nucleotide substitution on human health. The point mutation in the β-globin gene (Glu6Val) results in the production of sickle hemoglobin (HbS), which polymerizes under deoxygenated conditions, distorting erythrocyte morphology and triggering a cascade of vaso-occlusive, hemolytic, and inflammatory events. Despite being one of the most well-characterized inherited disorders, SCA remains a major global health burden, particularly in sub-Saharan Africa and regions with limited access to advanced care [1].Over the past few decades, therapeutic strategies for SCA have evolved from symptomatic management to disease-modifying interventions. Conventional approaches—such as hydroxyurea therapy, chronic transfusion, and hematopoietic stem cell transplantation—have significantly improved survival rates and quality of life. However, these interventions are constrained by issues of variable efficacy, treatment resistance, limited availability, and long-term complications. The need for curative and individualized solutions has driven an intense search for molecular and genomic innovations that target the disease at its genetic and mechanistic core [2-3].

Recent breakthroughs in biomarker discovery have deepened understanding of disease heterogeneity and prognosis. Inflammatory, oxidative, and genetic biomarkers now offer valuable insights into endothelial dysfunction, hemolytic intensity, and organ damage. Similarly, proteomic and metabolomic approaches have identified novel molecular signatures that enhance risk prediction and therapy monitoring. These biomarkers not only illuminate pathophysiological processes but also serve as gateways to personalized medicine, where treatment can be tailored based on a patient's molecular profile [4].Concurrently, the field of molecular therapy has witnessed transformative progress. The advent of gene addition and gene-editing technologies—such as CRISPR/Cas9, base editing, and lentiviral-mediated correction—has shifted the therapeutic paradigm from management to potential cure. These techniques aim to either replace the defective β-globin gene or reactivate endogenous fetal hemoglobin (HbF) production, thereby mitigating HbS polymerization and clinical complications. In parallel, small molecule drugs and RNA-based therapies are being developed to modulate gene expression and cellular pathways involved in erythropoiesis and oxidative balance [5].

Emerging Biomarkers in Sickle Cell Anemia

Biomarkers have become pivotal in transforming the management of SCA from empiric symptom-based care to mechanism-driven and predictive medicine. Given the heterogeneity in clinical presentation—ranging from mild hemolysis to severe vaso-occlusive crises and organ dysfunction—biomarkers serve as indispensable tools for risk stratification, early diagnosis, therapeutic monitoring, and prognostication. Recent advances in molecular biology and omics technologies have revealed a wide spectrum of biomarkers that reflect the complex

interplay of hemolysis, inflammation, endothelial activation, and oxidative stress underlying SCA pathophysiology [6].

1. Inflammatory and Endothelial Biomarkers

Chronic inflammation is a defining feature of SCA, driven by recurrent vaso-occlusion, hemolysis, and ischemia-reperfusion injury. Elevated plasma concentrations of pro-inflammatory cytokines such as interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor-alpha (TNF-α) are consistently associated with increased disease severity and frequency of painful crises. In addition, soluble adhesion molecules including vascular cell adhesion molecule-1 (sVCAM-1), E-selectin, and P-selectin reflect endothelial activation and promote leukocyte adhesion, contributing to vaso-occlusion and tissue injury. These markers not only aid in identifying patients at high risk of complications but also serve as potential therapeutic targets for anti-inflammatory and anti-adhesive interventions (Table 1) [7-8].

2. Oxidative Stress and Hemolytic Markers

Oxidative stress, resulting from the imbalance between reactive oxygen species (ROS) generation and antioxidant defense, is central to SCA pathogenesis. Biomarkers such as malondialdehyde (MDA), advanced oxidation protein products (AOPP), and asymmetric dimethylarginine (ADMA) indicate ongoing oxidative injury and endothelial dysfunction. Concurrently, markers of hemolysis—lactate dehydrogenase (LDH), bilirubin, and plasma free hemoglobin—reflect intravascular red cell destruction and correlate with complications like pulmonary hypertension and leg ulcers. Monitoring these biomarkers provides critical insights into the degree of hemolysis and vascular stress, thereby guiding antioxidant and anti-hemolytic therapeutic strategies [9-10].

3. Genetic and Epigenetic Modifiers

Genetic polymorphisms play a crucial role in determining disease severity and therapeutic responsiveness in SCA. Among these, variants in BCL11A, HBS1L-MYB, and KLF1 genes are recognized as potent modulators of fetal hemoglobin (HbF) production. Elevated HbF levels mitigate HbS polymerization and ameliorate clinical symptoms, making these genetic loci both biomarkers of disease severity and molecular targets for therapy. Beyond DNA sequence variation, epigeneticmodifications, including DNA methylation and microRNA expression, are emerging as sensitive indicators of disease state and treatment response. For instance, microRNAs such as miR-144 and miR-451have been implicated in erythroid differentiation and oxidative regulation, offering promising biomarker potential for monitoring disease dynamics and therapeutic efficacy [11-12].

4. Proteomic and Metabolomic Signatures

Advances in high-throughput proteomics and metabolomics have provided a systems-level understanding of SCA. Differential expression of plasma proteins such as hemopexin, haptoglobin, ceruloplasmin, and ferritin reveals insights into hemolytic burden, iron metabolism, and oxidative injury. Metabolomic studies have identified alterations in arginine, nitric oxide, and redox-related pathways, reflecting endothelial dysfunction and vaso-occlusive propensity. Integrating

proteomic and metabolomic signatures enables the development of composite biomarker panels that can capture disease complexity more comprehensively than single markers [13-14].

5. Cellular and Hematologic Biomarkers

Traditional hematologic indices remain valuable for clinical monitoring. Elevated white blood cell (WBC) counts, increased reticulocyte percentage, and altered platelet activity are associated with higher rates of vaso-occlusive crises and organ damage. Moreover, the proportion of fetal hemoglobin (HbF%) continues to serve as a robust predictor of disease severity and treatment outcome, particularly in patients on hydroxyurea therapy. Emerging interest in cell-derived microparticles and circulating endothelial cells also highlights novel cellular biomarkers reflecting vascular injury and coagulative stress [15].

Translational Relevance of Biomarker Discovery

The clinical translation of these biomarkers has redefined disease monitoring in SCA. Multi-biomarker panels combining inflammatory, oxidative, and genetic indicators can enhance diagnostic precision, predict complications, and identify patients most likely to benefit from molecular therapies such as HbF inducers or gene editing. Additionally, the integration of biomarker profiling into clinical trials facilitates real-time assessment of therapeutic efficacy and safety, paving the way for precision-guided interventions (16-17].

Table 1: Summary of Emerging Biomarkers in Sickle Cell Anemia

Biomarker Type	Examples	Clinical Relevance
Inflammatory	IL-6, IL-8, TNF-α, sVCAM-1	Predicts vaso-occlusive crises and endothelial activation
Oxidative Stress	MDA, ADMA, Cell-free Hb	Reflects hemolysis and redox imbalance
Genetic/Epigenetic	BCL11A, KLF1, miR-144	Modulates HbF and disease severity
Proteomic/Metabolomic	Hemopexin, Ceruloplasmin	Indicates tissue injury and oxidative stress
Hematologic	HbF%, Reticulocyte count	Correlates with clinical severity and therapy response

Molecular Therapies in Sickle Cell Anemia

The emergence of molecular therapies represents one of the most transformative developments in the history of SCA management. Unlike conventional treatments that mitigate symptoms or prevent complications, molecular therapies directly target the genetic and molecular underpinnings of the disease. These innovations seek either to correct the β-globin mutation, reprogram hemoglobin expression, or modulate disease pathways through precise molecular intervention. As such, they are redefining the therapeutic landscape and heralding the era of curative and individualized medicine in SCA (Table 2).

1. Gene Addition Therapy

Gene addition, or gene transfer therapy, was the first molecular strategy to achieve clinical success in SCA. It involves the introduction of a functional β-globin gene into autologous hematopoietic stem cells (HSCs) using a lentiviral vector, allowing for the production of anti-sickling hemoglobin. One of the most promising constructs, LentiGlobinBB305, incorporates a modified β-globin gene encoding the T87Q substitution, which inhibits HbS polymerization. Patients treated with this vector have demonstrated significant

increases in total hemoglobin and fetal hemoglobin, coupled with marked reductions in vaso-occlusive events and transfusion requirements.
This approach offers the advantage of using the patient's own stem cells, thereby eliminating graft-versus-host disease (GVHD) risk associated with allogeneic transplantation. However, challenges remain regarding vector integration safety, manufacturing costs, and long-term durability of gene expression [18-19].

2. Gene Editing and Gene Correction Strategies

The advent of precision gene editing technologies such as CRISPR/Cas9, zinc finger nucleases (ZFNs), and transcription activator-like effector nucleases (TALENs) has revolutionized molecular therapeutics in SCA. Rather than adding new genetic material, these tools directly modify the patient's genome to correct or silence pathogenic mutations.One highly successful strategy focuses on disrupting the BCL11A enhancer region, which normally represses fetal hemoglobin (HbF) synthesis after birth. Editing this locus reactivates endogenous HbF production, effectively compensating for defective HbS. The **e**xa-cel (formerly CTX001) clinical trial, based on CRISPR/Cas9 editing of the BCL11A enhancer, has shown remarkable outcomes—patients achieving transfusion independence and near-elimination of vaso-occlusive crises, with durable HbF levels exceeding 40%.Another innovative approach uses base editing to convert specific DNA nucleotides without creating double-strand breaks, minimizing off-target effects. This precision editing technology enables direct correction of the sickle mutation (Glu6Val), thereby restoring normal hemoglobin synthesis. Collectively, these strategies underscore the potential for lifelong remission through single-intervention therapy [20-21].

3. RNA-Based Therapeutics

RNA-targeted therapies have emerged as versatile tools to modulate gene expression and protein function in SCA. Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) can suppress transcriptional repressors or alter splicing patterns to enhance HbF expression. For instance, RNA-based modulation of BCL11A or MYB transcripts can mimic the therapeutic benefits of genetic editing without permanent genomic alteration. Additionally, synthetic mRNA platforms hold promise for transient expression of therapeutic globin or antioxidant proteins. These approaches offer reversibility and potentially improved safety profiles, providing flexible alternatives for patients ineligible for stem cell–based interventions [22-23].

4. Pharmacologic Modulators of Hemoglobin Function

Small-molecule agents remain a critical bridge between traditional pharmacotherapy and molecular interventions. Voxelotor (GBT440), an allosteric modulator of hemoglobin, stabilizes the oxygenated state of HbS, reducing polymerization and subsequent hemolysis. Clinical trials have shown sustained increases in hemoglobin levels and decreased markers of hemolysis, leading to its approval as a disease-modifying drug.
Other agents, such as crizanlizumab, a monoclonal antibody targeting P-selectin, reduce vaso-occlusive crises by inhibiting cellular adhesion. Furthermore, decitabine and butyratederivatives function as epigenetic modulators that enhance HbF expression, offering pharmacologic alternatives to hydroxyurea for HbF induction [24].

5. Stem Cell and Cellular Therapies

Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only established curative treatment for SCA.

However, its application is limited by donor availability, immune complications, and conditioning-related toxicities. Advances in non-myeloablative conditioning, haploidentical transplantation, andgene-corrected autologous transplantation are expanding accessibility while reducing risk. The convergence of gene editing and autologous transplantation is especially promising, combining curative efficacy with improved safety by avoiding donor-derived immune responses. Moreover, emerging cellulartherapies, including engineered mesenchymal stromal cells and immune-modulatory cell infusions, are being explored for vascular repair, anti-inflammatory effects, and reduction of vaso-occlusive injury [25-26].

Table 2: Overview of Molecular Therapies in Sickle Cell Anemia

Therapeutic Strategy	Mechanism	Clinical Status
Gene Addition	Lentiviral β-globin transfer	Phase II–III trials, promising outcomes
Gene Editing	CRISPR/Cas9-mediated HbF reactivation	Advanced clinical evaluation
RNA-Based Therapy	Modulation of globin gene expression	Preclinical and early trials
HbF Inducers	Pharmacologic upregulation (e.g., voxelotor)	Approved for clinical use
Stem Cell Transplantation	Replacement of defective HSCs	Curative but limited by donor availability

Translational and Clinical Implications

The translation of molecular discoveries into clinical practice marks a pivotal shift in the management paradigm of sickle cell anemia (SCA). The integration of emerging biomarkers and molecular therapies is not merely advancing scientific understanding but also redefining patient care through precision-based strategies. These innovations bridge laboratory research and bedside application, enabling early diagnosis, individualized treatment planning, and improved long-term outcomes.

1. Biomarkers as Predictive and Monitoring Tools

The clinical utility of biomarkers extends beyond disease characterization to real-time monitoring and therapeutic guidance. Inflammatory, oxidative, and endothelial biomarkers—such as IL-6, TNF-a, sVCAM-1, and cell-free hemoglobin—can predict impending vaso-occlusive crises or identify patients at high risk for pulmonary hypertension and organ injury. Genetic and epigenetic markers, including BCL11A and KLF1 variants, not only forecast disease severity but also help stratify candidates for molecular interventions such as hydroxyurea, gene therapy, or CRISPR-based editing.Proteomic and metabolomic profiles further refine this predictive framework by providing multidimensional insights into cellular metabolism, redox status, and vascular health. When integrated with machine learning algorithms, these biomarker datasets can facilitate dynamic risk modeling, leading to earlier interventions and better prognostic accuracy. Thus, biomarker-guided precision medicine is emerging as a cornerstone of modern SCA care [27].

2. Personalization of Therapeutic Strategies

The heterogeneity of SCA necessitates tailored approaches that account for genetic background, biomarker patterns, and therapeutic responsiveness. Biomarker panels can guide decisions on when to initiate hydroxyurea or escalate to gene-based therapy, ensuring that interventions are timely and effective. For instance, patients with low HbF and high inflammatory biomarker profiles may

benefit from HbF-inducing or anti-inflammatory therapies, while those with specific genetic variants might be optimal candidates for genome editing.This personalized framework also enables pharmacogenomic optimization. Understanding how genetic polymorphisms affect drug metabolism and efficacy can prevent toxicity and improve outcomes. As molecular and cellular therapies evolve, incorporating biomarker data into patient selection criteria will ensure that high-cost interventions are targeted to those most likely to achieve durable benefit [28-29].

3. Integration of Molecular Therapies into Clinical Practice

The transition of molecular therapies—from clinical trials to real-world implementation—requires robust translational infrastructure. The success of gene addition and CRISPR-based therapies in clinical studies has proven curative potential, yet scaling these interventions for widespread clinical use presents logistical, ethical, and economic challenges. Autologous gene-edited stem cell transplantation, for instance, demands sophisticated laboratory facilities, stringent safety monitoring, and long-term patient follow-up.To address these barriers, collaborative models integrating academic institutions, biotechnology firms, and health ministries are crucial. Simplifying production pipelines, developing cost-effective delivery systems, and training healthcare professionals in genomic medicine will accelerate the equitable dissemination of molecular therapies. In low-resource regions, decentralized centers of excellence could facilitate access while maintaining regulatory oversight and safety standards [30-33].

4. Ethical, Social, and Economic Considerations

The rapid progression of molecular therapies raises important ethical questions surrounding accessibility, affordability, and informed consent. In many regions where SCA is most prevalent, healthcare inequities threaten to widen as advanced treatments remain inaccessible to those in need. Ethical frameworks must therefore emphasize justice, ensuring that innovation aligns with social equity.Moreover, patient education and genetic counseling are vital for promoting understanding of the benefits and risks of gene editing, stem cell transplantation, and molecular diagnostics. Health economists and policymakers must collaborate to develop funding mechanisms, subsidies, and insurance models that support long-term affordability while maintaining sustainability of care [34-37].

5. Toward a Precision Medicine Future

The fusion of biomarker science and molecular therapy heralds the dawn of precisionhematology—a clinical model where prevention, diagnosis, and treatment are customized to individual molecular profiles. Artificial intelligence–driven data integration, combined with next-generation sequencing and high-throughput omics, will enable predictive modeling of disease progression and treatment outcomes. This paradigm allows clinicians to anticipate complications before they arise and tailor curative interventions with maximal efficacy and minimal toxicity.In the near future, routine clinical workflows may include molecular profiling at diagnosis, dynamic biomarker monitoring during therapy, and post-treatment genomic surveillance. These integrative strategies will not only improve survival but also enhance quality of life, transforming SCA from a chronic, debilitating illness into a controllable, and potentially curable, molecular condition[38-40].

Conclusion

Sickle cell anemia (SCA) stands at the intersection of molecular pathology and translational innovation—a disease once

confined to symptomatic management that is now on the cusp of molecular cure. The rapid evolution of biomarker discovery and molecular therapy has reshaped the clinical landscape, offering unprecedented opportunities for prediction, prevention, and personalization of care. Biomarkers now serve not only as diagnostic and prognostic tools but also as molecular compasses guiding therapeutic choices and monitoring treatment efficacy.At the same time, gene-based interventions—ranging from lentiviral gene addition to CRISPR/Cas9-mediated editing and RNA-targeted modulation—have demonstrated that it is possible to address the genetic root of SCA rather than its downstream complications. These therapies, when coupled with biomarker-informed precision strategies, hold the potential to achieve durable remission or functional cure.However, the translation of these scientific triumphs into real-world clinical impact demands more than technological progress. It requires equitable access, robust infrastructure, ethical governance, and sustained investment in research and capacity building—particularly in regions where the disease burden is greatest. The challenge for the next decade lies not only in perfecting the science but in democratizing its benefits.

References

1. Inusa, B. P. D., Hsu, L. L., Kohli, N., Patel, A., Ominu-Evbota, K., Anie, K. A., & Atoyebi, W. (2019). Sickle Cell Disease-Genetics, Pathophysiology, Clinical Presentation and Treatment. *International journal of neonatal screening*, *5*(2), 20. https://doi.org/10.3390/ijns5020020

2. Salinas Cisneros, G., & Thein, S. L. (2020). Recent Advances in the Treatment of Sickle Cell Disease. *Frontiers in physiology*, *11*, 435. https://doi.org/10.3389/fphys.2020.00435

3. Adewoyin A. S. (2015). Management of sickle cell disease: a review for physician education in Nigeria (sub-saharan Africa). *Anemia*, *2015*, 791498. https://doi.org/10.1155/2015/791498

4. Liu, J., Yang, L., Liu, D., Wu, Q., Yu, Y., Huang, X., Li, J., & Liu, S. (2025). The role of multi-omics in biomarker discovery, diagnosis, prognosis, and therapeutic monitoring of tissue repair and regeneration processes. *Journal of orthopaedic translation*, *54*, 131–151. https://doi.org/10.1016/j.jot.2025.07.006

5. Uddin, F., Rudin, C. M., & Sen, T. (2020). CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future. *Frontiers in oncology*, *10*, 1387. https://doi.org/10.3389/fonc.2020.01387

6. Kalpatthi, R., & Novelli, E. M. (2018). Measuring success: utility of biomarkers in sickle cell disease clinical trials and care. *Hematology. American Society of Hematology. Education Program*, *2018*(1), 482–492. https://doi.org/10.1182/asheducation-2018.1.482

7. Conran, N., & Belcher, J. D. (2018). Inflammation in sickle cell disease. *Clinical hemorheology and microcirculation*, *68*(2-3), 263–299. https://doi.org/10.3233/CH-189012

8. Ansari, J., & Gavins, F. N. E. (2019). Ischemia-Reperfusion Injury in Sickle Cell Disease: From Basics to Therapeutics. *The American journal of pathology*, *189*(4), 706–718. https://doi.org/10.1016/j.ajpath.2018.12.012

9. Dash, U. C., Bhol, N. K., Swain, S. K., Samal, R. R., Nayak, P. K., Raina, V., Panda, S. K.,

Kerry, R. G., Duttaroy, A. K., & Jena, A. B. (2025). Oxidative stress and inflammation in the pathogenesis of neurological disorders: Mechanisms and implications. *Acta pharmaceutica Sinica. B*, *15*(1), 15–34. https://doi.org/10.1016/j.apsb.2024.10.004

10. S, S., Hegde, S. V., Agarwal, S. V., Ns, D., Pillai, A., Shah, S. N., & S, R. (2024). Biomarkers of Oxidative Stress and Their Clinical Relevance in Type 2 Diabetes Mellitus Patients: A Systematic Review. *Cureus*, *16*(8), e66570. https://doi.org/10.7759/cureus.66570

11. Mohammad, S. N. N. A., Iberahim, S., Wan Ab Rahman, W. S., Hassan, M. N., Edinur, H. A., Azlan, M., & Zulkafli, Z. (2022). Single Nucleotide Polymorphisms in *XMN1-HBG2*, *HBS1L-MYB*, and *BCL11A* and Their Relation to High Fetal Hemoglobin Levels That Alleviate Anemia. *Diagnostics (Basel, Switzerland)*, *12*(6), 1374. https://doi.org/10.3390/diagnostics12061374

12. Mikobi, T. M., Tshilobo Lukusa, P., Aloni, M. N., Lumaka, A. Z., Kaba, D. K., Devriendt, K., Matthijs, G., Mbuyi Muamba, J. M., & Race, V. (2018). Protective BCL11A and HBS1L-MYB polymorphisms in a cohort of 102 Congolese patients suffering from sickle cell anemia. *Journal of clinical laboratory analysis*, *32*(1), e22207. https://doi.org/10.1002/jcla.22207

13. Smith, A., & McCulloh, R. J. (2015). Hemopexin and haptoglobin: allies against heme toxicity from hemoglobin not contenders. *Frontiers in physiology*, *6*, 187. https://doi.org/10.3389/fphys.2015.00187

14. Schaer, D. J., Vinchi, F., Ingoglia, G., Tolosano, E., & Buehler, P. W. (2014). Haptoglobin, hemopexin, and related defense pathways-basic science, clinical perspectives, and drug development. *Frontiers in physiology*, *5*, 415. https://doi.org/10.3389/fphys.2014.00415

15. Heeney, M. M., & Ware, R. E. (2010). Hydroxyurea for children with sickle cell disease. *Hematology/oncology clinics of North America*, *24*(1), 199–214. https://doi.org/10.1016/j.hoc.2009.11.002

16. Bodaghi, A., Fattahi, N., & Ramazani, A. (2023). Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases. *Heliyon*, *9*(2), e13323. https://doi.org/10.1016/j.heliyon.2023.e13323

17. Qoronfleh, M. W., & Al-Dewik, N. (2025). Cancer Biomarkers: Reflection on Recent Progress, Emerging Innovations, and the Clinical Horizon. *Cancers*, *17*(18), 2981. https://doi.org/10.3390/cancers17182981

18. Abraham, A. A., & Tisdale, J. F. (2021). Gene therapy for sickle cell disease: moving from the bench to the bedside. *Blood*, *138*(11), 932–941. https://doi.org/10.1182/blood.2019003776

19. Germino-Watnick, P., Hinds, M., Le, A., Chu, R., Liu, X., & Uchida, N. (2022). Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease. *Cells*, *11*(11), 1843. https://doi.org/10.3390/cells11111843

20. Gaj, T., Gersbach, C. A., & Barbas, C. F., 3rd (2013). ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. *Trends in biotechnology*, *31*(7), 397–405. https://doi.org/10.1016/j.tibtech.2013.04.004

21. Obeagu, E. I., & Obeagu, G. U. (2024). Malnutrition in sickle cell anemia: Prevalence, impact, and interventions: A Review. *Medicine*, *103*(20), e38164.

https://doi.org/10.1097/MD.0000000000038164

22. Obeagu E. I. (2024). Maximizing longevity: erythropoietin's impact on sickle cell anaemia survival rates. *Annals of medicine and surgery (2012)*, *86*(3), 1570–1574. https://doi.org/10.1097/MS9.0000000000001763

23. Gaj, T., Sirk, S. J., Shui, S. L., & Liu, J. (2016). Genome-Editing Technologies: Principles and Applications. *Cold Spring Harbor perspectives in biology*, *8*(12), a023754. https://doi.org/10.1101/cshperspect.a023754

24. Watts, J. K., & Corey, D. R. (2012). Silencing disease genes in the laboratory and the clinic. *The Journal of pathology*, *226*(2), 365–379. https://doi.org/10.1002/path.2993

25. Zhu, Y., Zhu, L., Wang, X., & Jin, H. (2022). RNA-based therapeutics: an overview and prospectus. *Cell death & disease*, *13*(7), 644. https://doi.org/10.1038/s41419-022-05075-2

26. Glaros, A. K., Razvi, R., Shah, N., & Zaidi, A. U. (2021). Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor. *Therapeutic advances in hematology*, *12*, 20406207211001136. https://doi.org/10.1177/20406207211001136

27. Bhalla, N., Bhargav, A., Yadav, S. K., & Singh, A. K. (2023). Allogeneic hematopoietic stem cell transplantation to cure sickle cell disease: A review. *Frontiers in medicine*, *10*, 1036939. https://doi.org/10.3389/fmed.2023.1036939

28. Obeagu, E. I., & Obeagu, G. U. (2024). Management of diabetes mellitus patients with sickle cell anemia: Challenges and therapeutic approaches. *Medicine*, *103*(17), e37941. https://doi.org/10.1097/MD.0000000000037941

29. Obeagu, E. I., & Obeagu, G. U. (2024). Managing gastrointestinal challenges: Diarrhea in sickle cell anemia. *Medicine*, *103*(18), e38075. https://doi.org/10.1097/MD.0000000000038075

30. Gyurkocza, B., Rezvani, A., & Storb, R. F. (2010). Allogeneic hematopoietic cell transplantation: the state of the art. *Expert review of hematology*, *3*(3), 285–299. https://doi.org/10.1586/ehm.10.21

31. Khurana, K., Mahajan, S., Acharya, S., Kumar, S., & Toshniwal, S. (2024). Clinical Biomarkers of Acute Vaso-Occlusive Sickle Cell Crisis. *Cureus*, *16*(3), e56389. https://doi.org/10.7759/cureus.56389

32. Silva, D. G., Belini Junior, E., Carrocini, G. C., Torres, L.deS., Ricci Júnior, O., Lobo, C. L., Bonini-Domingos, C. R., & de Almeida, E. A. (2013). Genetic and biochemical markers of hydroxyurea therapeutic response in sickle cell anemia. *BMC medical genetics*, *14*, 108. https://doi.org/10.1186/1471-2350-14-108

33. McGann, P. T., & Ware, R. E. (2015). Hydroxyurea therapy for sickle cell anemia. *Expert opinion on drug safety*, *14*(11), 1749–1758. https://doi.org/10.1517/14740338.2015.1088827

34. Chehelgerdi, M., Chehelgerdi, M., Khorramian-Ghahfarokhi, M., Shafieizadeh, M., Mahmoudi, E., Eskandari, F., Rashidi, M., Arshi, A., & Mokhtari-Farsani, A. (2024). Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. *Molecular cancer*, *23*(1), 9. https://doi.org/10.1186/s12943-023-01925-5

35. Lee, T. L., & Sawai, T. (2024). Navigating equity in global access to genome therapy expanding access to potentially transformative therapies and benefiting those in need requires global policy changes. *Frontiers in genetics*, *15*, 1381172. https://doi.org/10.3389/fgene.2024.1381172

36. Djordjevic, D., McFadyen, A., & Anderson, J. A. (2023). Ethical challenges and opportunities in the development and approval of novel therapeutics for rare diseases. *The journal of medicine access*, *7*, 27550834231177507. https://doi.org/10.1177/27550834231177507

37. Wang, S. X., Huang, Z. F., Li, J., Wu, Y., Du, J., & Li, T. (2024). Optimization of diagnosis and treatment of hematological diseases via artificial intelligence. *Frontiers in medicine*, *11*, 1487234. https://doi.org/10.3389/fmed.2024.1487234

38. Obeagu, E. I., & Obeagu, G. U. (2024). Implications of climatic change on sickle cell anemia: A review. *Medicine*, *103*(6), e37127. https://doi.org/10.1097/MD.0000000000037 12

39. Obeagu, E. I., Ubosi, N. I., Obeagu, G. U., Egba, S. I., & Bluth, M. H. (2024). Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications. *Medicine*, *103*(2), e36898. https://doi.org/10.1097/MD.0000000000036 898

40. Obeagu, E. I., & Obeagu, G. U. (2024). Telomere Dynamics in Sickle Cell Anemia: Unraveling Molecular Aging and Disease Progression. *Journal of blood medicine*, *15*, 313–323. https://doi.org/10.2147/JBM.S462758